Antibody Drug Conjugates Market Size (2024 - 2029)

The Antibody Drug Conjugates market is projected to experience significant growth over the forecast period, driven by factors such as the increasing prevalence of cancer, a rising geriatric population, and heightened R&D activities for novel therapeutics. Despite the adverse impacts of the COVID-19 pandemic on business operations and demand, the market is expected to expand due to the post-pandemic approvals and launches of antibody drug conjugates. The market's growth is further supported by increased investments, which are anticipated to enhance the ADC pipeline and broaden its applications. However, challenges such as stringent government regulations and high manufacturing costs may hinder the market's expansion.

Market Size of Antibody Drug Conjugates Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Antibody Drug Conjugates Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 12.05 Billion
Market Size (2029) USD 44.05 Billion
CAGR (2024 - 2029) 29.57 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Antibody Drug Conjugates Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Antibody Drug Conjugates Market Analysis

The Antibody Drug Conjugates Market size is estimated at USD 12.05 billion in 2024, and is expected to reach USD 44.05 billion by 2029, growing at a CAGR of 29.57% during the forecast period (2024-2029).

The COVID-19 pandemic had a notable impact on the antibody drug conjugate market since many cancer consultations and treatments were postponed or canceled due to the lockdown restrictions. For instance, according to the National Health Service (NHS) of the United Kingdom, in 2023, there was a shortfall in cancer treatments during the pandemic, driven by a sharp drop in urgent referrals as people needed the stay-at-home due to the lockdown restrictions, which significantly reduced the demand for overall cancer therapies including antibody drug conjugate (ADC).

Moreover, according to the Annual Report 2022 of Seagen Inc., a leading manufacturer of antibody drug conjugate (ADC), the COVID-19 pandemic had adverse impacts on the ADC companies business, including commercialization efforts, supply chain, regulatory activities, clinical development activities, and others. Thus, the COVID-19 pandemic significantly impacted the business operations of ADC manufacturing companies, thus impacting the sale of antibody drug conjugate. However, the increasing approvals and launches of antibody drug conjugate in the post-pandemic period attain growth in the market over the coming years.

The major factors responsible for the growth of the ADC market include the growing prevalence of cancer, the increasing geriatric population, and increasing R&D activities for the development of novel therapeutics. Antibody drug conjugates offer one of the most effective treatments for cancer patients. They can exploit the specificity of monoclonal antibodies toward targeted antigens for the release of potential cytotoxic drugs, with increased activity and decreased toxicity as compared to chemotherapies.

The rising incidence of cancer in various countries increases the usage of ADC for treatment. For instance, according to the May 2022 update by the Canadian Cancer Society, 28,600 Canadian women were diagnosed with breast cancer in 2022, representing 25% of all new cancer cases in women in 2022. Also, on average, 78 Canadian women were expected to be diagnosed with breast cancer daily in 2022. Thus, owing to the high prevalence and increase in the probability of acquiring breast cancer among females, the demand for antibody drug conjugates is likely to rise, fueling the market growth over the forecast period.

The increasing investments in the ADC market are expected to boost the antibody drug conjugate pipeline and expand its applications, which may positively impact the market's growth. For instance, in June 2022, Spirea Limited secured funding of GBP 2.4 (USD 3.06) million with investments from high-profile investors from the United Kingdom and the United States. The company uses these funds to initiate its pipeline of superior and differentiated ADC in the treatment of solid tumors, thereby contributing to the growth of the market.

However, the stringent government regulations and high manufacturing costs of antibody drug conjugate are expected to restrain the market's growth over the forecast period.

Antibody Drug Conjugates Industry Segmentation

Antibody drug conjugates are a class of biopharmaceuticals designed for the treatment of cancer, comprising an antibody that specifically targets a tumor antigen and a cytotoxic compound connected via a chemical linker. These are intended to allow the specific targeting of the cytotoxic compound to kill cancer cells while having a limited effect on healthy tissue.

The antibody drug conjugates market is segmented by product type (adcetris, kadcyla, and other product types), application (blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and other applications), technology (cleavable linker and non-cleavable linker), target type (CD30 antibodies, HER2 antibodies, and other target types), end user (hospitals and specialty cancer centers, biotechnology and pharmaceutical companies, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated antibody drug conjugates market sizes and trends for 17 countries across major regions globally.

The report offers the value in USD for the above segments.

By Product Type
Adcetris
Kadcyla
Other Product Types
By Application
Blood Cancer
Breast Cancer
Ovary Cancer
Lung Cancer
Skin Cancer
Brain Tumor
Other Applications
By Technology
Clevable Linker
Non-cleavable Linker
By Target Type
CD30 Antibodies
HER2 Antibodies
Other Target Types
By End User
Hospitals and Speciality Cancer Centers
Biotechnology and Pharmaceutical Companies
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Antibody Drug Conjugates Market Size Summary

The antibody drug conjugates (ADC) market is poised for substantial growth, driven by the increasing prevalence of cancer and the rising geriatric population. ADCs are gaining traction as effective cancer treatments due to their ability to deliver cytotoxic drugs directly to cancer cells, minimizing toxicity compared to traditional chemotherapies. The market is experiencing a resurgence post-COVID-19, which had previously disrupted cancer treatments and ADC business operations. The pandemic's impact on supply chains, regulatory activities, and clinical development has been significant, but the subsequent approvals and launches of ADCs are expected to propel market expansion. The market's growth is further supported by heightened research and development activities aimed at developing novel therapeutics, alongside increasing investments that are expected to enhance the ADC pipeline and broaden its applications.

North America is anticipated to be a key region for market growth, fueled by technological advancements and a high incidence of cancer cases. The presence of major players and strategic initiatives in the United States and Canada are contributing to the region's expansion. The competitive landscape of the ADC market is characterized by the presence of several global and local companies, with key players like Seagen Inc., ImmunoGen Inc., and Pfizer Inc. holding significant market shares. Partnerships and new product approvals are pivotal in driving market growth, as evidenced by recent collaborations and licensing agreements. Despite the market's potential, challenges such as stringent government regulations and high manufacturing costs may pose constraints. Nonetheless, the ongoing development and approval of ADCs, particularly for breast cancer treatment, are expected to sustain the market's upward trajectory over the forecast period.

Explore More

Antibody Drug Conjugates Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Incidences of Cancer

      2. 1.2.2 Growing Geriatic Population

      3. 1.2.3 Increasing R&D Activities for the Development of Novel Therapeutics

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Government Regulations

      2. 1.3.2 High Manufacturing Costs of Antibody Drug Conjugates

    4. 1.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Buyers/Consumers

      2. 1.4.2 Bargaining Power of Suppliers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Product Type

      1. 2.1.1 Adcetris

      2. 2.1.2 Kadcyla

      3. 2.1.3 Other Product Types

    2. 2.2 By Application

      1. 2.2.1 Blood Cancer

      2. 2.2.2 Breast Cancer

      3. 2.2.3 Ovary Cancer

      4. 2.2.4 Lung Cancer

      5. 2.2.5 Skin Cancer

      6. 2.2.6 Brain Tumor

      7. 2.2.7 Other Applications

    3. 2.3 By Technology

      1. 2.3.1 Clevable Linker

      2. 2.3.2 Non-cleavable Linker

    4. 2.4 By Target Type

      1. 2.4.1 CD30 Antibodies

      2. 2.4.2 HER2 Antibodies

      3. 2.4.3 Other Target Types

    5. 2.5 By End User

      1. 2.5.1 Hospitals and Speciality Cancer Centers

      2. 2.5.2 Biotechnology and Pharmaceutical Companies

      3. 2.5.3 Other End Users

    6. 2.6 Geography

      1. 2.6.1 North America

        1. 2.6.1.1 United States

        2. 2.6.1.2 Canada

        3. 2.6.1.3 Mexico

      2. 2.6.2 Europe

        1. 2.6.2.1 Germany

        2. 2.6.2.2 United Kingdom

        3. 2.6.2.3 France

        4. 2.6.2.4 Italy

        5. 2.6.2.5 Spain

        6. 2.6.2.6 Rest of Europe

      3. 2.6.3 Asia-Pacific

        1. 2.6.3.1 China

        2. 2.6.3.2 Japan

        3. 2.6.3.3 India

        4. 2.6.3.4 Australia

        5. 2.6.3.5 South Korea

        6. 2.6.3.6 Rest of Asia-Pacific

      4. 2.6.4 Middle East and Africa

        1. 2.6.4.1 GCC

        2. 2.6.4.2 South Africa

        3. 2.6.4.3 Rest of Middle East and Africa

      5. 2.6.5 South America

        1. 2.6.5.1 Brazil

        2. 2.6.5.2 Argentina

        3. 2.6.5.3 Rest of South America

Antibody Drug Conjugates Market Size FAQs

The Antibody-drug Conjugates Market size is expected to reach USD 12.05 billion in 2024 and grow at a CAGR of 29.57% to reach USD 44.05 billion by 2029.

In 2024, the Antibody-drug Conjugates Market size is expected to reach USD 12.05 billion.

Antibody Drug Conjugates Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)